Exclusive interview with AstraZeneca on the future of oligonucleotide drug development

Given the resurgence of investment and investigation into oligonucleotides, the Oligonucleotide CMC & Analytical Development team did an exclusive interview with leading industry expert – Peter Smith, Principal Scientist, New Modalities, Oligonucleotides, AstraZeneca.

Peter shared fascinating insights into the current challenges at AstraZeneca, such as the major bottlenecks they are facing, how they are tackling cost and analytical requirements and what he believes is in store for the next phase of oligonucleotide drug development.

Here is a glance at some of what Peter had to say…

‘’Regarding oligonucleotide CMC considerations, one big opportunity that is already being realised during 2023 and will continue to be significantly important during the next 12 months and beyond is the continued development of alternative manufacturing paradigms such as liquid-phase oligonucleotide synthesis and, in addition to this, the parallel development of biocatalytic manufacturing technologies.’’

Take a look at the full interview here!

Peter and 60+ other industry experts will be uniting in Boston this August to continue the conversation as they share experiences and lessons learned. Stay at the forefront of this rapidly evolving space and be part of this exclusive.

For the full scope of this year’s meeting, access your copy of the full program here!